Home / Business and Economy / Marksans Pharma Profit Surges 8% in Q3 FY25
Marksans Pharma Profit Surges 8% in Q3 FY25
5 Feb
Summary
- Net profit increased by 8.26% to Rs 113.20 crore in December 2025 quarter.
- Sales saw a significant rise of 10.64% reaching Rs 754.43 crore.
- Operating Profit Margin (OPM) improved to 21.31% from 20.35%.
Marksans Pharma has reported robust financial performance for the quarter ending December 2025. The company's net profit saw a substantial increase of 8.26%, rising to Rs 113.20 crore from Rs 104.56 crore in the same quarter of the previous year.
Contributing to this profit growth, sales revenue surged by 10.64% to Rs 754.43 crore during the December 2025 quarter. This indicates a strong market demand and effective sales strategies. The company also demonstrated improved operational efficiency, with its Operating Profit Margin (OPM) increasing to 21.31% from 20.35% in the prior year's comparative quarter.
Further financial highlights for the quarter include a 7% rise in Profit Before Depreciation and Tax (PBDT) to Rs 174.95 crore and a 5% increase in Profit Before Tax (PBT) to Rs 150.62 crore. These figures underscore a period of consistent growth and profitability for Marksans Pharma.
